DOCSLIB.ORG

Prescription Medications and Hair Loss Or Thinning

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Prescription Medications and Hair Loss Or Thinning Prescription Medications and Hair Loss or Thinning There are a number of prescription drugs and over-the counter medications that have the side effect of interfering with the normal cycles of hair development and have been reported to cause hair loss. Though infrequent, it typically does not occur until a few weeks or after prolonged use of the particular prescription. There are other factors besides duration such as dosing and patient response. In most cases however but not all hair growth will resume after a few months after discontinuing the medication. When hair follicles are in the anagen phase of hair growth the individual hairs can continue to develop and grow for (36) to (48) months. When hair follicles are in the telogen phase of hair growth the individual hairs are in dormancy, which lasts about three months, the hair is dormant and then will fall out and replaced by new hair growth. Therefore the medical conditions caused by prescription drugs and over-the-counter medications are classified as these (2) types of hair loss: telogen effluvium and anagen effluvium. The following is a partial list of prescriptions and medications that effect the hair growth of new hairs or may even cause hair loss of existing hair through short-term or long-term use: Acne Medications All prescription drugs derived from vitamin A as treatments for acne or other relative conditions, including: • Isotretinoin (Sotret®, Claravis®, Amnesteem®, Accutane) • Tretinoin (various – Retin A®) • Tazarotene (Tazorac®) • Acitretin (Soriatane®) • Adapalene – (Differin®) Antidepressant and Antipsychotic Prescription Drugs • Amoxapine • Amitriptyline • Bupropion • Clomipramine • Desipramine • Doxepin • Fluoxetine • Haloperidol • Imipramine • Nortriptyline • Paroxetine • Sertraline Antibiotics and Antifungal drugs Antibiotics are known to reduce hemoglobin and also lower vitamin B levels • Levo Floaxin • Amoxicillin • Penicillin (Amoxicot, Kelfex) Blood Thinning Medications Various anticoagulants (blood thinners), including: • Panwarfin (warfarin sodium) • Sofarin (warfarin sodium) • Coumadin (warfarin sodium) • Heparin injections Chemotherapy Medications • Adriamycin • Bleomycin • Cactinomycin • Cyclophosphamide • Cytarabine • Dactinomycin • Daunorubicin • Docetaxel • Doxorubicin • Etoposide • Fluorouracil • Ifosfamide • Irinotecan • Methotrexate • Paclitaxel • Topttecan • Vinorelbine Cholesterol Medications Cholesterol-lowering drugs, including: • Atronid-S (Clofibrate) • Metoprolol (Toprol XL) • Atenol (Tenoretic) • Lopid (Gemfibrozil) Convulsions/ Epilepsy – Anticonvusant Prescription Medications • Tridone (Trimethadione) • Carbamazepine • Phenytoin • Sodium Valproate Depression – Antidepression Prescription Medications • Prozac (fluoxetine hydrochloride) • Zoloft (sertraline hydrochloride) • Paxil (paroxetine) • Anafranil (clomipramine) • Janimine (imipramine) • Tofranil (imipramine) • Tofranil PM (imipramine) • Adapin (doxepin) • Sinequan (doxepin) • Surmontil (trimipramine) • Pamelor (nortriptyline) • Ventyl (nortriptyline) • Elavin (amitriptyline) • Endep (amitriptyline) • Norpramin (desipramine) • Pertofrane (desipramine) • Vivactil (protriptyline hydrochloride) • Asendin (amoxapine) • Haldol ( haloperidol) Diet / Attention Deficit Disorders • Amphetamines • Methamphetamines • Methylphenidate Glaucoma These beta-blocker drugs include the following: • Timoptic Eye Drops (Timolol) • Timoptic Ocudose (Timolol) • Timoptic XC (Timolol) Gout Medications • Lopurin (Allopurinol) • Zyloprim (Allopurinol) Heart (High Blood Pressure) Medications Many prescription medications for the heart, including those known as the beta blockers, which are also used to treat high blood pressure, and include: • Tenormin (Atenolol) • Lopressor (Metoprolol) • Corgard (Nadolol) • Inderal and Inderal LA (Propanolol) • Blocadren (Timolol) Medications for Hormonal Conditions All hormone-containing prescriptions and/or medications prescribed for hormone-related, sexual dysfunction, reproductive, male and female-specific conditions have the potential to cause hair loss, including the following: • Birth Control Medications • Hormone-replacement therapy (HRT) for women (estrogen or progesterone) • Male androgenic hormones and all forms of testosterone (i.e. Testex, Depo-Testosterone, and Delatestryl) • Anabolic steriods o Fluoxymesterone (Halotestin) o Methyltestosterone (Android, Metandren, Oreton, Testred, Virilon) o Stanozolol (Winstrol) o Danazol (Danocrine) • Prednisone and other steroids Non-Inflammatory Prescriptions Many anti-inflammatory drugs, including those prescribed for localized pain, swelling and injury, and arthritis have been associated with thinning and hair loss. These nonsteroidal anti-inflammatory prescription drugs include the following: • Naprosyn (Naproxen) • Anaprox (Naproxen) • Anaprox DS (Naproxen) • Celecoxib (Celebrex) • Daypro (Oxaprozin) • Diclofenac (Voltaren) • Etodolac (Lodine) • Fenoprofen (Nalfon) • Indocin (indomethacin) • Indocin SR (indomethacin) • Ketoprofen (Orudis, Oruvail) • Relafen (Nabumetone) • Clinoril (Sulindac) Also there are anti-inflammatory medications that are used in combination with chemotherapy such as: • Methotrexate (MTX) • Rheumatex (Methotrexate) • Folex (Methotrexate) Prescription Medications for Parkinson's Disease • Levadopa / L-dopa (Dopar, Larodopa) Thyroid Disorder Prescription Medications • Many of the drugs used to treat the thyroid (i.e. Thiouracil) Ulcer Medications (Over-the-Counter and Prescription) There are several drugs used to treat indigestion, stomach difficulties, and ulcers, including over-the-counter and prescription medications which include: • Famotidine (Pepcid™) • Ranitidine (Zantac™) • Cimetidine (Tagamet™) .
Load more

Recommended publications
  • Comparative Effects of Cimetidine and Famotidine on the Vagally Stimulated Acid Secretion in the Isolated Mouse Whole Stomach
    Comparative Effects of Cimetidine and Famotidine on the Vagally Stimulated Acid Secretion in the Isolated Mouse Whole Stomach Kazuo Watanabe1, Shingo Yano1, Masayuki Yamamoto1 and Shoko Kanaoka2 1Laboratory of Chemical Pharmacology, Department of Drug Evaluation and Toxicological Sciences, Faculty of Pharmaceutical Sciences, Chiba University, 1-33, Yayoi-cho, Inage-ku, Chiba 263, Japan 2Research Institute for Wakan-Yaku, Toyama Medical and Pharmaceutical University, Toyama 930-01, Japan Received July 15, 1992 Accepted December 10, 1992 ABSTRACT-We investigated the effects of cimetidine and famotidine on the acid secretory response to elec trical vagal stimulation, bethanechol and histamine in the isolated mouse whole stomach preparation. The acid secretion elicited by electrical vagal stimulation at the position of the esophagus (10 Hz, 0.3 msec, 10 V for 5 min) was reproducible by repeated stimulation in each preparation, and it was abolished by tetrodo toxin, atropine and hexamethonium. This vagally stimulated acid secretion was abolished by cimetidine (3 mM), while it was only partly inhibited by famotidine (10-100 ƒÊM). Histamine (100 ƒÊM)-induced acid secre tion was inhibited by cimetidine and famotidine, and the doses of these drugs required for complete inhibi tion were 3 mM and 10 ƒÊM, respectively. In contrast, bethanechol (10 ƒÊM)-induced acid secretion was slight ly reduced by famotidine (1-100 ƒÊM), but markedly reduced by cimetidine (3 mM). In the guinea pig ileum, millimolar concentrations of cimetidine and famotidine shifted the dose-response curve of the contractile response to acetylcholine rightward. These findings suggest that the inhibitory effect of cimetidine on the vagally stimulated or bethanechol-induced acid secretion is elicited at least partly through mechanisms different from H2-antagonism.
    [Show full text]
  • A Comparative Evaluation of Lafutidine and 2 Rabeprazole in The
    1 *Original research paper 2 A comparative evaluation of Lafutidine and 3 Rabeprazole in the treatment of gastritis and 4 peptic ulcer: A double-blind, randomized study 5 in Indian patients. 6 Dr. Sanjay Kumar 1, Dr. Bhupesh Dewan 2*, Deepashri Shah 2 7 8 1Global Liver and Gastroenterology Centre, Bhopal, India 2 9 Medical Department, Zuventus Healthcare Ltd., Mumbai, India 10 11 . 12 ABSTRACT 13 Aims: To assess the efficacy of lafutidine therapy versus rabeprazole in Indian patients with endoscopically and histologically proven gastritis and peptic ulcer. Study design: A double blind, double dummy, randomized, comparative study. Place and Duration of Study: Global Liver and Gastroenterology Centre, Bhopal, India, between March 2010 and October 2010. Methodology: A total of 100 patients were enrolled, including 50 with endoscopically and histologically proven gastritis and other 50 with peptic ulcer (over 5 mm in diameter). Each group was randomized to receive either lafutidine or rabeprazole tablet and their corresponding competitor placebo dummy tablet, for a period of 4 weeks. Gastritis/ulcer cure rates confirmed by endoscopic histology, symptom response and Helicobacter pylori (H. Pylori) eradication were compared among the two drugs Results: Complete cure of gastritis was observed in all the patients (100%) treated with lafutidine and 95.24% [20/21; 95% CI: 76.18 to 99.88%] patients treated with rabeprazole. Complete cure of ulcer was observed in 72.0% (18/25, 95% CI = 50.61 to 87.93%) and 79.16% (19/24, 95% CI = 57.85 to 92.87%) patients treated with lafutidine and rabeprazole respectively. There was no significant difference in gastritis/ulcer cure rate and symptom response rate between the two treatment groups at the end of the study.
    [Show full text]
  • Receptor Antagonist (H RA) Shortages | May 25, 2020 2 2 2 GERD4,5 • Take This Opportunity to Determine If Continued Treatment Is Necessary
    H2-receptor antagonist (H2RA) Shortages Background . 2 H2RA Alternatives . 2 Therapeutic Alternatives . 2 Adults . 2 GERD . 3 PUD . 3 Pediatrics . 3 GERD . 3 PUD . 4 Tables Table 1: Health Canada–Approved Indications of H2RAs . 2 Table 2: Oral Adult Doses of H2RAs and PPIs for GERD . 4 Table 3: Oral Adult Doses of H2RAs and PPIs for PUD . 5 Table 4: Oral Pediatric Doses of H2RAs and PPIs for GERD . 6 Table 5: Oral Pediatric Doses of H2RAs and PPIs for PUD . 7 References . 8 H2-receptor antagonist (H2RA) Shortages | May 25, 2020 1 H2-receptor antagonist (H2RA) Shortages BACKGROUND Health Canada recalls1 and manufacturer supply disruptions may be causing shortages of commonly used acid-reducing medications called histamine H2-receptor antagonists (H2RAs) . H2RAs include cimetidine, famotidine, nizatidine and ranitidine . 2 There are several Health Canada–approved indications of H2RAs (see Table 1); this document addresses the most common: gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD) . 2 TABLE 1: HEALTH CANADA–APPROVED INDICATIONS OF H2RAs H -Receptor Antagonists (H RAs) Health Canada–Approved Indications 2 2 Cimetidine Famotidine Nizatidine Ranitidine Duodenal ulcer, treatment ü ü ü ü Duodenal ulcer, prophylaxis — ü ü ü Benign gastric ulcer, treatment ü ü ü ü Gastric ulcer, prophylaxis — — — ü GERD, treatment ü ü ü ü GERD, maintenance of remission — ü — — Gastric hypersecretion,* treatment ü ü — ü Self-medication of acid indigestion, treatment and prophylaxis — ü† — ü† Acid aspiration syndrome, prophylaxis — — — ü Hemorrhage from stress ulceration or recurrent bleeding, — — — ü prophylaxis ü = Health Canada–approved indication; GERD = gastroesophageal reflux disease *For example, Zollinger-Ellison syndrome .
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Effectiveness and Tolerability of Different Recommended Doses Of
    www.nature.com/scientificreports OPEN Effectiveness and Tolerability of Different Recommended Doses of PPIs and H2RAs in GERD: Network Received: 26 April 2016 Accepted: 15 December 2016 Meta-Analysis and GRADE system Published: 19 January 2017 Chao Zhang1, Joey S. W. Kwong2, Rui-Xia Yuan1,3, Hao Chen4, Chang Xu5, Yi-Pin Wang1, Gong-Li Yang6, Jin-Zhu Yan1, Le Peng1, Xian-Tao Zeng1, Hong Weng1, Jie Luo1 & Yu-Ming Niu1,6 Proton pump inhibitors (PPIs) and histamine-2-receptor antagonists (H2RAs) are used for gastro- esophageal reflux disease (GERD); however, the clinical evidence for treatment is poor. We evaluated the effectiveness and tolerability of different doses of PPIs,2 H RAs and placebo in adults with GERD. Six online databases were searched through September 1, 2016. All related articles were included and combined with a Bayesian network meta-analysis from randomized controlled trials (RCTs). The GRADE systems were employed to assess the main outcome. Ninety-eight RCTs were identified, which included 45,964 participants. Our analysis indicated that the full/standard dose of esomeprazole at 40 mg per day was the most efficient in healing among nine different dosages of PPIs and2 H RAs. The main efficacy outcome did not change after adjustments for the area, age, level of disease from endoscopy, year of publication, pharmaceutical industry sponsorship, Intention-to-treat (ITT)/per-protocol (PP), withdrawal rate, pre-set select design bias, single blinded and unblinded studies, study origination in China, study arms that included zero events, inconsistency node or discontinued drug were accounted for in the meta-regressions and sensitivity analyses.
    [Show full text]
  • Wednesday, June 12, 2019 4:00Pm
    Wednesday, June 12, 2019 4:00pm Oklahoma Health Care Authority 4345 N. Lincoln Blvd. Oklahoma City, OK 73105 The University of Oklahoma Health Sciences Center COLLEGE OF PHARMACY PHARMACY MANAGEMENT CONSULTANTS MEMORANDUM TO: Drug Utilization Review (DUR) Board Members FROM: Melissa Abbott, Pharm.D. SUBJECT: Packet Contents for DUR Board Meeting – June 12, 2019 DATE: June 5, 2019 Note: The DUR Board will meet at 4:00pm. The meeting will be held at 4345 N. Lincoln Blvd. Enclosed are the following items related to the June meeting. Material is arranged in order of the agenda. Call to Order Public Comment Forum Action Item – Approval of DUR Board Meeting Minutes – Appendix A Update on Medication Coverage Authorization Unit/Use of Angiotensin Converting Enzyme Inhibitor (ACEI)/ Angiotensin Receptor Blocker (ARB) Therapy in Patients with Diabetes and Hypertension (HTN) Mailing Update – Appendix B Action Item – Vote to Prior Authorize Aldurazyme® (Laronidase) and Naglazyme® (Galsulfase) – Appendix C Action Item – Vote to Prior Authorize Plenvu® [Polyethylene Glycol (PEG)-3350/Sodium Ascorbate/Sodium Sulfate/Ascorbic Acid/Sodium Chloride/Potassium Chloride] – Appendix D Action Item – Vote to Prior Authorize Consensi® (Amlodipine/Celecoxib) and Kapspargo™ Sprinkle [Metoprolol Succinate Extended-Release (ER)] – Appendix E Action Item – Vote to Update the Prior Authorization Criteria For H.P. Acthar® Gel (Repository Corticotropin Injection) – Appendix F Action Item – Vote to Prior Authorize Fulphila® (Pegfilgrastim-jmdb), Nivestym™ (Filgrastim-aafi),
    [Show full text]
  • Ranitidine Protocol – Final Confidential Version 1.0 – 17Th January 2020 PASS Information
    RANITIDINE AND OTHER HISTAMINE-H2-RECEPTOR ANTAGONISTS – A DRUG UTILISATION STUDY Principal Investigators Katia Verhamme, MD, PhD Department of Medical Informatics EMC – Rotterdam Peter Rijnbeek, PhD Department of Medical Informatics EMC - Rotterdam Document Status Final Version 1.0 Date of final version of the study 17th January 2020 report EU PAS register number 1 EMA TENDER – Ranitidine protocol – Final Confidential Version 1.0 – 17th January 2020 PASS information Title Ranitidine and other histamine H2-receptor antagonists – a drug utilisation study Protocol version identifier V1.0 Final Date of last version of protocol 2020-01-17 EU PAS register number Active Ingredient Ranitidine Cimetidine Famotidine Nizatidine Niperotidine Roxatidine Ranitidine bismuth citrate Lafutidine Medicinal product Ranitidine Product reference Procedure number Marketing authorisation holder(s) Joint PASS Research question and objectives Ranitidine is a competitive and reversible inhibitor of the action of histamine and indicated for the management of peptic ulceration, Gastro-Esophageal Reflux Disease (GERD), reflux oesophagitis and Zollinger-Ellison syndrome. Results of a preliminary laboratory analysis have shown the presence of N-Nitrosodimethylamine (NDMA), a human carcinogen, in ranitidine. With this DUS, we aim to determine drug utilisation and prescription patterns of medicinal products containing H2-receptor antagonists. These data will give insight on the number of patients using ranitidine and thus potentially at risk of NDMA. In particular we will: 1. Study the prevalence and incidence prescribing of H2-receptor antagonists as a class and by individual drug 2 EMA TENDER – Ranitidine protocol – Final Confidential Version 1.0 – 17th January 2020 2. Explore the characteristics of H2-receptor antagonist use with regard to age (10-years age categories), sex, formulation, daily dose, duration and cumulative exposure by class level and individual ingredient 3.
    [Show full text]
  • ARISTADA INITIO® Prescribing Information
    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ___________________ CONTRAINDICATIONS ___________________ ARISTADA INITIO® safely and effectively. See full prescribing Known hypersensitivity to aripiprazole (4). information for ARISTADA INITIO®. _______________ WARNINGS AND PRECAUTIONS _______________ ARISTADA INITIO® (aripiprazole lauroxil) extended-release injectable • Cerebrovascular Adverse Reactions in Elderly Patients with Dementia- suspension, for intramuscular use Related Psychosis: Increased incidence of cerebrovascular adverse Initial U.S. Approval: 2015 reactions (e.g., stroke, transient ischemia attack, including fatalities) (5.2). • Potential for Dosing and Medication Errors: Substitution and dispensing WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS errors between ARISTADA INITIO and ARISTADA could occur. Do not WITH DEMENTIA-RELATED PSYCHOSIS substitute ARISTADA INITIO for ARISTADA (5.3). See full prescribing information for complete boxed warning. • Neuroleptic Malignant Syndrome: Manage with immediate discontinuation and close monitoring (5.4). • Elderly patients with dementia-related psychosis treated with • Tardive Dyskinesia: Discontinue if clinically appropriate (5.5). antipsychotic drugs are at an increased risk of death. (5.1) • Metabolic Changes: Monitor for hyperglycemia, dyslipidemia, and weight • ARISTADA INITIO is not approved for the treatment of patients with gain (5.6). dementia-related psychosis. (5.1) • Pathological Gambling and Other Compulsive Behaviors:
    [Show full text]
  • New and Future Drug Development for Gastroesophageal Reflux Disease
    J Neurogastroenterol Motil, Vol. 20 No. 1 January, 2014 pISSN: 2093-0879 eISSN: 2093-0887 http://dx.doi.org/10.5056/jnm.2014.20.1.6 JNM Journal of Neurogastroenterology and Motility Review New and Future Drug Development for Gastroesophageal Reflux Disease Carla Maradey-Romero and Ronnie Fass* The Esophageal and Swallowing Center, Division of Gastroenterology and Hepatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA Medical therapy remains the most popular treatment for gastroesophageal reflux disease (GERD). Whilst interest in drug devel- opment for GERD has declined over the last few years primarily due to the conversion of most proton pump inhibitor (PPI)’s to generic and over the counter compounds, there are still numerous areas of unmet needs in GERD. Drug development has been focused on potent histamine type 2 receptor antagonist’s, extended release PPI’s, PPI combination, potassium-competitive acid blockers, transient lower esophageal sphincter relaxation reducers, prokinetics, mucosal protectants and esophageal pain modulators. It is likely that the aforementioned compounds will be niched for specific areas of unmet need in GERD, rather than compete with the presently available anti-reflux therapies. (J Neurogastroenterol Motil 2014;20:6-16) Key Words Erosive esophagitis; Gastroesophageal reflux; Heartburn; Proton pump inhibitors Most patients with GERD fall into 1 of 3 categories: non- erosive reflux disease (NERD), erosive esophagitis (EE), and Introduction Barrett’s esophagus (BE). The 2 main phenotypes of GERD, Gastroesophageal reflux disease (GERD) is a common con- NERD and EE, appear to have different pathophysiological and dition that develops when reflux of stomach contents cause trou- clinical characteristics.
    [Show full text]
  • Pepcid® (Famotidine) Tablets
    9883042 PEPCID® (FAMOTIDINE) TABLETS DESCRIPTION ® The active ingredient in PEPCID (famotidine) is a histamine H2-receptor antagonist. Famotidine is N′­ (aminosulfonyl)-3-[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]thio]propanimidamide. The empirical formula of famotidine is C H N O S and its molecular weight is 337.43. Its structural formula is: 8 15 7 2 3 Famotidine is a white to pale yellow crystalline compound that is freely soluble in glacial acetic acid, slightly soluble in methanol, very slightly soluble in water, and practically insoluble in ethanol. Each tablet for oral administration contains either 20 mg or 40 mg of famotidine and the following inactive ingredients: hydroxypropyl cellulose, hypromellose, iron oxides, magnesium stearate, microcrystalline cellulose, corn starch, talc, titanium dioxide, and carnauba wax. CLINICAL PHARMACOLOGY IN ADULTS GI Effects PEPCID is a competitive inhibitor of histamine H2-receptors. The primary clinically important pharmacologic activity of PEPCID is inhibition of gastric secretion. Both the acid concentration and volume of gastric secretion are suppressed by PEPCID, while changes in pepsin secretion are proportional to volume output. In normal volunteers and hypersecretors, PEPCID inhibited basal and nocturnal gastric secretion, as well as secretion stimulated by food and pentagastrin. After oral administration, the onset of the antisecretory effect occurred within one hour; the maximum effect was dose-dependent, occurring within one to three hours. Duration of inhibition of secretion by doses of 20 and 40 mg was 10 to 12 hours. Single evening oral doses of 20 and 40 mg inhibited basal and nocturnal acid secretion in all subjects; mean nocturnal gastric acid secretion was inhibited by 86% and 94%, respectively, for a period of at least 10 hours.
    [Show full text]
  • Early Effects of Oral Administration of Omeprazole and Roxatidine on Intragastric Ph
    Iida et al. / J Zhejiang Univ-Sci B (Biomed & Biotechnol) 2012 13(1):29-34 29 Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology) ISSN 1673-1581 (Print); ISSN 1862-1783 (Online) www.zju.edu.cn/jzus; www.springerlink.com E-mail: [email protected] Early effects of oral administration of omeprazole and roxatidine on intragastric pH Hiroshi IIDA1, Shingo KATO1, Yusuke SEKINO1, Eiji SAKAI1, Takashi UCHIYAMA1, Hiroki ENDO1, Kunihiro HOSONO1, Yasunari SAKAMOTO1, Koji FUJITA1, Masato YONEDA1, Tomoko KOIDE1, Hirokazu TAKAHASHI1, Chikako TOKORO1, Ayumu GOTO1, Yasunobu ABE1, Noritoshi KOBAYASHI1, Kensuke KUBOTA1, Eiji GOTOH2, Shin MAEDA1, Atsushi NAKAJIMA1, Masahiko INAMORI†‡1,3 (1Gastroenterology Division, Yokohama City University School of Medicine, Yokohama 236-0004, Japan) (2Department of Medical Education, Yokohama City University School of Medicine, Yokohama 236-0004, Japan) (3Office of Postgraduate Medical Education, Yokohama City University Hospital, Yokohama 236-0004, Japan) †E-mail: [email protected] Received Mar. 14, 2011; Revision accepted Aug. 30, 2011; Crosschecked Dec. 2, 2011 Abstract: Objective: The ideal medication for the treatment of acid-related diseases, e.g., peptic ulcers, stress- related gastric bleeding, functional dyspepsia, and gastroesophageal reflux disease, should have a rapid onset of action to promote hemostasis and relieve the symptoms. The aim of our study was to investigate the inhibitory effects on gastric acid secretion of a single oral administration of a proton pump inhibitor, omeprazole 20 mg, and an H2-receptor antagonist, roxatidine 75 mg. Methods: Ten Helicobacter pylori-negative male subjects participated in this randomized, two-way crossover study. Intragastric pH was monitored continuously for 6 h after single oral admini- stration of omeprazole 20 mg and roxatidine 75 mg.
    [Show full text]
  • Histamine H2-Receptor Antagonism of T-593: Studies on Positive Chronotropic Responses in Guinea Pig Atria
    Histamine H2-Receptor Antagonism of T-593: Studies on Positive Chronotropic Responses in Guinea Pig Atria Hirotoshi Arai, Masaya Nakagawa, Kikuko Tanada, Hidetoshi Yamaguchi and Shiro Hirai Research Laboratories, Toyama Chemical Co., Ltd., 2-4-1 Shimookui, Toyama 930, Japan Received September 1, 1993 Accepted January 11, 1994 ABSTRACT-Histamine H2-antagonistic properties of the novel H2-antagonist T-593, (±)-N-[2-hydroxy-2 (4-hydroxyphenyl)ethyl]-N [2-[[[5-(methylamino)methyl-2-furyl]methyl] thio]ethyl] -N"-(methylsulfonyl) guanidine were investigated on the histamine-induced positive chronotropic responses in isolated guinea pig right atria. T-593 at 3 x 10-1-3 x 10-6 M suppressed the maximal responses of the histamine concentration response curves in a concentration-dependent fashion, indicating that T-593 is an unsurmountable an tagonist. The pD'2 values were 5.50 for T-593 and 5.61 for famotidine; and the IC50 values at 1 x 10-5 M histamine were 1.05 x 10-6 M for T-593, 1.59 x 10-6 M for ranitidine and 1.67 x 10-7 M for famotidine. T-593 is a racemic compound composed of two enantiomers, (-)-T-593 and (+)-T-593. The histamine H2 antagonistic activity of (-)-T-593 was 1.5-fold more potent than that of racemic T-593, but (+)-T-593 scarce ly inhibited the histamine-induced positive chronotropic response. Histamine H2-antagonism by racemic T-593 was mainly attributed to (-)-T-593. Isoproterenol-induced positive chronotropic responses were not affected by T-593 even at 3 x 10-5 M.
    [Show full text]